日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Delphi consensus for the third-line treatment of metastatic colorectal cancer

德尔菲共识:转移性结直肠癌三线治疗

García-Alfonso, Pilar; Vera, Ruth; Aranda, Enrique; Élez, Elena; Rivera, Fernando

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

MRTX1719 是一种 MTA 协同 PRMT5 抑制剂,在 MTAP 缺失型癌症的临床前模型和患者中表现出合成致死性。

Lars D Engstrom ,Ruth Aranda ,Laura Waters ,Krystal Moya ,Vickie Bowcut ,Laura Vegar ,David Trinh ,Allan Hebbert ,Christopher R Smith ,Svitlana Kulyk ,J David Lawson ,Leo He ,Laura D Hover ,Julio Fernandez-Banet ,Jill Hallin ,Darin Vanderpool ,David M Briere ,Alice Blaj ,Matthew A Marx ,Jordi Rodon ,Michael Offin ,Kathryn C Arbour ,Melissa L Johnson ,David J Kwiatkowski ,Pasi A Jänne ,Candace L Haddox ,Kyriakos P Papadopoulos ,Jason T Henry ,Konstantinos Leventakos ,James G Christensen ,Ronald Shazer ,Peter Olson

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers

基于片段发现 MRTX1719,这是一种用于治疗 MTAP 缺失癌症的 PRMT5•MTA 复合物的合成致死抑制剂

Christopher R Smith, Ruth Aranda, Thomas P Bobinski, David M Briere, Aaron C Burns, James G Christensen, Jeffery Clarine, Lars D Engstrom, Robin J Gunn, Anthony Ivetac, Ronald Jean-Baptiste, John M Ketcham, Masakazu Kobayashi, Jon Kuehler, Svitlana Kulyk, J David Lawson, Krystal Moya, Peter Olson, L

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

KRASG12C 抑制剂 MRTX849 可重塑肿瘤免疫微环境,增强肿瘤对检查点抑制剂疗法的敏感性

David M Briere, Shuai Li, Andrew Calinisan, Niranjan Sudhakar, Ruth Aranda, Lauren Hargis, David H Peng, Jiehui Deng, Lars D Engstrom, Jill Hallin, Sole Gatto, Julio Fernandez-Banet, Adam Pavlicek, Kwok-Kin Wong, James G Christensen, Peter Olson

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

KRASG12C 抑制剂 MRTX849 为小鼠模型和患者中 KRAS 突变型癌症的治疗敏感性提供了见解

Jill Hallin, Lars D Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R Baer, Joshua A Ballard, Michael R Burkard, Jay B Fell, John P Fischer, Guy P Vigers, Yaohua Xue, Sole Gatto, Julio Fernandez-Banet, Adam Pavlicek, Karen Velastagui, R

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

I/IV类HDAC抑制剂莫西替诺司他可增强肿瘤抗原呈递,减少免疫抑制细胞类型,并增强免疫检查点抑制剂疗法的效果。

David Briere ,Niranjan Sudhakar ,David M Woods ,Jill Hallin ,Lars D Engstrom ,Ruth Aranda ,Harrah Chiang ,Andressa L Sodré ,Peter Olson ,Jeffrey S Weber ,James G Christensen

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

格莱沙替尼在携带 MET 外显子 14 突变的肺癌模型和患者中表现出抗肿瘤活性,并在非临床模型中克服了突变介导的对 I 型 MET 抑制剂的耐药性

Lars D Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A Tovar, Curt J Essenburg, Zachary Madaj, Harrah Chiang, David Briere, Jill Hallin, Pedro P Lopez-Casas, Natalia Baños, Camino Menendez, Manuel Hidalgo, Vanessa Tassell, Richard Chao, Darya I Chudova, Richard B Lanman, Peter Olson, Lyudmilla Bazhe